Miguel Ángel Herrera Enríquez

Prof. Miguel Ángel Herrera Enríquez

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017
Verified
Book Chapter
Open access
PDF file
ACAndrés Eliú Castell-Rodríguez
Andrés Eliú Castell-Rodríguez
GPGabriela Piñon-Zarate
Gabriela Piñon-Zarate
Miguel Ángel Herrera EnríquezMiguel Ángel Herrera Enríquez
Miguel Ángel Herrera Enríquez
KJKatia Jarquín-Yáñez
Katia Jarquín-Yáñez
IMIliana Medina-Solares
Iliana Medina-Solares
Dendritic cells (DCs) are antigen-presenting cells derived from bone marrow precursors and form a widely distributed cellular system throughout the body. DCs exert immune-surveillance for exogenous and endogenous antigens and the later activation of naive T lymphocytes giving rise to various immunological responses. Different growth factors and cytokines can modulate the differentiation and function of DCs, GM-CSF, M-CSF, Flt3, and TGF-β, resulting in a large variety of DCs with different functional abilities. Thus, DCs are classified as plasmacytoid DCs (pDCs), conventional DCs (cDCs), and DCs derived from monocytes (mDCs). Functionally, the cDCs may be divided into two states: immature and mature. Immature DCs are specialist in uptaking and processing antigens; in contrast, mature DCs are professional in antigen presentation. It has been observed that immature cDCs can induce immune tolerance while mature cDCs may induce Th2 or Th1 immune responses. It is worth noting that different subpopulations of DCs have the ability to secrete different cytokine patterns, resulting in the induction of different immunological responses. Furthermore DCs are involved in the pathophysiology of several diseases such as contact hypersensitivity, autoimmune diseases, or cancer, but they can also be used as therapeutic tools in these conditions.

1 January 2019 in Journal of Immunotoxicology
Verified
Journal Article
Open access
SCSandra Castro-Gamboa
Sandra Castro-Gamboa
MGMaritza Roxana Garcia-Garcia
Maritza Roxana Garcia-Garcia
GPGabriela Piñon-Zarate
Gabriela Piñon-Zarate
MRMarcela Rojas-Lemus
Marcela Rojas-Lemus
KJKatia Jarquin-Yáñez
Katia Jarquin-Yáñez
NBNina Bogdanchikova
Nina Bogdanchikova
Silver nanoparticles (AgNP) are one of the most studied nanoparticles due to their anti-bacterial, -fungal, -viral, -parasitic, and -inflammatory properties. This raises the need to evaluate the toxicity and biological effects of AgNP in the immune system in order to develop new safer biomedical products. In this study, an AgNP formulation currently approved for veterinary applications was applied to mouse bone marrow-derived dendritic cells (BMDC), considered important antigen-presenting cells of the immune system, to evaluate cytotoxicity, genotoxicity, and any significant influence on expression of cellular markers associated with BMDC phenotype and maturation status. The results showed that after 12 h of AgNP exposure, a significant decrease in BMDC viability occurred at the highest concentration tested (1.0 µg AgNP/ml) and at lower doses, the cells maintained membrane integrity and metabolic activity. DNA damage was not significant with any AgNP level aside from the 1.0 µg AgNP/ml level. Regarding phenotype, no differences in expression of CD40 (co-stimulatory molecule highly present in mature BMDC) or in CD273 (a marker for inhibitory T-cell response) were observed. The current results showed that the toxicity of this AgNP formulation was dose-related. The findings also suggest BMDC could maintain structural conservation of co-stimulatory/co-inhibitory surface molecules after 12 h of exposure to this AgNP. This work represents the first step in identifying the toxic effects of this AgNP formulation on dendritic cells.

9 June 2015 in Theoretical Biology and Medical Modelling
Verified
Journal Article
Open access
PDF file
ECE. Castillo-Montiel
E. Castillo-Montiel
JCJuan Carlos Chimal-Eguía
Juan Carlos Chimal-Eguía
JTJ.Ignacio Tello
J.Ignacio Tello
GPG. Piñon-Zaráte
G. Piñon-Zaráte
Miguel Ángel Herrera EnríquezMiguel Ángel Herrera Enríquez
Miguel Ángel Herrera Enríquez
ACAndrés Eliú Castell-Rodríguez
Andrés Eliú Castell-Rodríguez
The immunotherapy using dendritic cells (DCs) against different varieties of cancer is an approach that has been previously explored which induces a specific immune response. This work presents a mathematical model of DCs immunotherapy for melanoma in mice based on work by Experimental Immunotherapy Laboratory of the Medicine Faculty in the Universidad Autonoma de Mexico (UNAM). The model is a five delay differential equation (DDEs) which represents a simplified view of the immunotherapy mechanisms. The mathematical model takes into account the interactions between tumor cells, dendritic cells, naive cytotoxic T lymphocytes cells (inactivated cytotoxic cells), effector cells (cytotoxic T activated cytotoxic cells) and transforming growth factor β cytokine (T G F−β). The model is validated comparing the computer simulation results with biological trial results of the immunotherapy developed by the research group of UNAM. The results of the growth of tumor cells obtained by the control immunotherapy simulation show a similar amount of tumor cell population than the biological data of the control immunotherapy. Moreover, comparing the increase of tumor cells obtained from the immunotherapy simulation and the biological data of the immunotherapy applied by the UNAM researchers obtained errors of approximately 10 %. This allowed us to use the model as a framework to test hypothetical treatments. The numerical simulations suggest that by using more doses of DCs and changing the infusion time, the tumor growth decays compared with the current immunotherapy. In addition, a local sensitivity analysis is performed; the results show that the delay in time “ τ”, the maximal growth rate of tumor “r” and the maximal efficiency of tumor cytotoxic cells rate “aT” are the most sensitive model parameters. By using this mathematical model it is possible to simulate the growth of the tumor cells with or without immunotherapy using the infusion protocol of the UNAM researchers, to obtain a good approximation of the biological trials data. It is worth mentioning that by manipulating the different parameters of the model the effectiveness of the immunotherapy may increase. This last suggests that different protocols could be implemented by the Immunotherapy Laboratory of UNAM in order to improve their results.

20 February 2024 in Polymers
Verified
Journal Article
Open access
PDF file
KJKatia Jarquin-Yáñez
Katia Jarquin-Yáñez
Miguel Ángel Herrera EnríquezMiguel Ángel Herrera Enríquez
Miguel Ángel Herrera Enríquez
DBDiego Ivan Benítez-Barrera
Diego Ivan Benítez-Barrera
FSFrancisco Manuel Sánchez-Arévalo
Francisco Manuel Sánchez-Arévalo
JBJorge Alejandro Benitez_Martinez
Jorge Alejandro Benitez_Martinez
ACAndrés Eliú Castell-Rodríguez
Andrés Eliú Castell-Rodríguez
The development of injectable hydrogels with natural biopolymers such as gelatin (Ge) and hyaluronic acid (Ha) is widely performed due to their biocompatibility and biodegradability. The combination of both polymers crosslinked with N-Ethyl-N′-(3-dimethyl aminopropyl) carbodiimide hydrochloride (EDC) can be used as an innovative dermal filler that stimulates fibroblast activity and increases skin elasticity and tightness. Thus, crosslinked Ge/Ha hydrogels with different concentrations of EDC were administered subcutaneously to test their efficacy in young and old rats. At higher EDC concentrations, the viscosity decreases while the particle size of the hydrogels increases. At all concentrations of EDC, amino and carboxyl groups are present. The histological analysis shows an acute inflammatory response, which disappears seven days after application. At one and three months post-treatment, no remains of the hydrogels are found, and the number of fibroblasts increases in all groups in comparison with the control. In addition, the elastic modulus of the skin increases after three months of treatment. Because EDC-crosslinked Ge/Ha hydrogels are biocompatible and induce increased skin tension, fibroblast proliferation, and de novo extracellular matrix production, we propose their use as a treatment to attenuate wrinkles and expression lines.

21 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
GPGabriela Piñon-Zarate
Gabriela Piñon-Zarate
FRFernanda Reyes-Riquelme
Fernanda Reyes-Riquelme
MSMa Beatriz Sánchez-Monroy
Ma Beatriz Sánchez-Monroy
MVMónica Velasco-Torrez
Mónica Velasco-Torrez
MMMariano Martínez-Vázquez
Mariano Martínez-Vázquez
ACAndrés Eliú Castell-Rodríguez
Andrés Eliú Castell-Rodríguez
Dendritic cells are antigen-presenting cells, which identify and process pathogens to subsequently activate specific T lymphocytes. To regulate the immune responses, DCs have to mature by the recognition of TLR ligands, TNFα or IFNγ. These ligands have been used as adjuvants to activate DCs in situ or in vitro, with toxic effects. It has been shown that some molecules affect the immune system, e.g., Masticadienonic acid (MDA) and 3α-hydroxy masticadienoic acid (3α-OH MDA) triterpenes naturally occurring in several medicinal plants, since they activate the nitric oxide synthase in macrophages and induce T lymphocyte proliferation. The DCs maturation induced by MDA or 3a-OH MDA was determined by incubating these cells with MDA or 3α-OH MDA, and their phenotype was afterwards analyzed. The results showed that only 3α-OH MDA was able to induce DCs maturation. When mice with melanoma were inoculated with DCs/3α-OH MDA, a decreased tumor growth rate was observed along with an extended cell death area within tumors compared to mice treated with DCs incubated with MDA. In conclusion, it is proposed that 3α-OH MDA may be an immunostimulant molecule. Conversely, it is proposed that MDA may be a molecule with anti-inflammatory properties.

30 October 2022 in Polymers
Verified
Journal Article
Open access
PDF file
GPGabriela Piñon-Zarate
Gabriela Piñon-Zarate
BHBeatriz Hernández-Téllez
Beatriz Hernández-Téllez
KJKatia Jarquin-Yáñez
Katia Jarquin-Yáñez
Miguel Ángel Herrera EnríquezMiguel Ángel Herrera Enríquez
Miguel Ángel Herrera Enríquez
AFAmérica Eréndira Fuerte-Pérez
América Eréndira Fuerte-Pérez
ACAndrés Eliú Castell-Rodríguez
Andrés Eliú Castell-Rodríguez
The half-time of cells and molecules used in immunotherapy is limited. Scaffolds-based immunotherapy against cancer may increase the half-life of the molecules and also support the migration and activation of leukocytes in situ. For this purpose, the use of gelatin (Ge)/hyaluronic acid (HA) scaffolds coupled to CpG and the tumor antigen MAGE-A5 is proposed. Ge and HA are components of the extracellular matrix that stimulate cell adhesion and activation of leucocytes; CpG can promote dendritic cell maturation, and MAGE-A5 a specific antitumor response. C57BL/6 mice were treated with Ge/HA/scaffolds coupled to MAGE-A5 and/or CpG and then challenged with the B16-F10 melanoma cell line. Survival, tumor growth rate and the immune response induced by the scaffolds were analyzed. Ge/HA/CpG and Ge/HA/MAGE-A5 mediated dendritic cell maturation and macrophage activation, increased survival, and decreased the tumor growth rate and a tumor parenchyma with abundant cell death areas and abundant tumor cells with melanin granules. Only the scaffolds coupled to MAGE-A5 induced the activation of CD8 T cells. In conclusion, Ge/HA scaffolds coupled to CpG or MAGE-A5, but not the mixture, can induce a successful immune response capable of promoting tumor cell clearance and increased survival.